Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Crescent Biopharma, Inc.NASDAQ: CBIO
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $25.77M rose 81.2% year over year, behind the +230.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 74.8% from the prior quarter. Over 3 fiscal years it compounded at +51.0% a year.
Context
- Operating expenses amounted to 1507.5% of revenue in FY2025.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +81.2% toward the trailing-twelve-month pace of +230.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 163.48M USD
- Year-over-year change
- +227.6%
- 4-year CAGR
- +26.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 163.48M | +227.6% |
| FY2024 | 2024-12-31 | 49.9M | +27.0% |
| FY2023 | 2023-12-31 | 39.29M | -17.3% |
| FY2022 | 2022-12-31 | 47.48M | -26.5% |
| FY2021 | 2021-12-31 | 64.61M | — |
Operating Expenses vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +230.2% is the 2nd highest of 10, against a peer median of -0.7%.
- Operating expenses amounts to 1472.9% of revenue for CBIO, versus a peer median of 195.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $596M USD | -0.7% | +16.7% | 509.4% | |
| LTM Sep 2026 | $333.75M USD | +278.1% | +101.5% | 297994.6% | |
| LTM Sep 2026 | $217.29M USD | +5.9% | -11.0% | 81.7% | |
| LTM Mar 2026 | $175.02M USD | +230.2% | +51.0% | 1472.9% | |
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $99.95M USD | -10.4% | -13.9% | 281.2% | |
| LTM Mar 2026 | $74.43M USD | +18.8% | +19.7% | — | |
| LTM Mar 2026 | $43.51M USD | +37.6% | +37.2% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥34.74M CNY | -93.5% | -66.4% | — |
| LTM Mar 2026 | $33.28M USD | -2.6% | -8.4% | 45.8% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | -0.7% | -8.4% | 195.8% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.16M | 75K | 10K | 0 | 10.84M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.16M | 75K | 10K | 0 | 10.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M |
| Selling, General & Admin | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M |
| Operating Expenses | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| EBITDA | (63.18M) | (47.2M) | (39.12M) | (44.17M) | (149.67M) |
| EBITDA Margin | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| Operating Income | (63.45M) | (47.4M) | (39.28M) | (49.9M) | (152.63M) |
| Operating Margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Interest Income | 19.77K | 714.52K | 2.38M | 1M | 2.88M |
| Interest Expense | 0 | 0 | 0 | 852K | 2.19M |
| Other Income / Expenses | 19.77K | 714.96K | 2.38M | 1.37M | 690K |
| Income Before Tax | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (151.94M) |
| Pre-Tax Margin | -5469.0% | -62251.1% | -368987.8% | — | -1401.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2M |
| Net Income | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (153.94M) |
| Net Margin | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (Basic) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| EPS (Diluted) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| Weighted Avg Shares | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
| Weighted Avg Shares (Diluted) | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.